Chiron Partners with Biometric Imaging to Leverage New Cell Analysis Platform.MOUNTAIN VIEW and EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 6, 1996--Chiron Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CHIR CHIR Chiricahua National Monument (US National Park Service) ) and Biometric Imaging Inc., today announced a preferred partnership agreement to explore the use of Biometric Imaging's microvolume fluorimetry platform for cellular analysis. "This relationship gives Chiron an important new way to deliver our chemistries using Biometric Imaging's convenient platform," said Abla Creasey, Ph.D., senior director of research and development, Chiron Technologies. "This will allow us to provide more value to clinicians, a key aim of Chiron's Therametrics(TM) initiative: the ability to measure disease states and enable clinicians to tailor therapies." "Microvolume fluorimetry is a key technological breakthrough that has already been introduced for use in several clinical applications," said Bala S. Manian The creator of this article, or someone who has substantially contributed to it, may have a conflict of interest regarding its subject matter. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. , Ph.D., Biometric Imaging's chairman. "We expect the preferred partnership with Chiron to broaden the scope of the microvolume fluorimetry platform in clinical settings such as oncology and infectious diseases." A proprietary technology of Biometric Imaging, microvolume fluorimetry is a laser-based imaging system which detects fluorescently-tagged cells held in stasis in a defined volume. This enabling technology provides, for the first time, an automated cellular assay delivery system, with applications in emerging fields of medicine, including cell therapy, where accuracy and convenience of use in clinical setting are important features. Biometric Imaging's IMAGN 2000(R) platform and its first application, the 4T8(TM) assay, have been cleared by the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for CD4+ and CD8+ cell analysis and is used as a diagnostic for monitoring HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. progression. The preferred partnership agreement is a long-term commitment between the two companies, and includes an equity investment by Chiron in Biometric Imaging. Financial terms were not disclosed. Founded in 1991, privately held Biometric Imaging is the first company to address the critical need for standardized cellular analysis procedures in the emerging field of cell therapy. Cell therapy uses transfused cells from a patient or donor to achieve a desired therapeutic effect in diseases such as cancer and AIDS. The company has developed and is marketing a novel, enabling technology called microvolume fluorimetry to provide rapid, precise and easy-to-perform cell enumeration 1. (mathematics) enumeration - A bijection with the natural numbers; a counted set. Compare well-ordered. 2. (programming) enumeration - enumerated type. , as well as real time cell characterization in routine clinical settings. Biometric Imaging's products are designed to: 1) help ensure the integrity of transfused products; 2) optimize cell therapy procedures; and 3) monitor disease progression and the efficacy of therapy. Chiron Corporation is a science-driven healthcare company that combines diagnostic, vaccine and therapeutic strategies for controlling disease. Chiron participates in four global healthcare markets: diagnostics, including immunodiagnostics, critical care diagnostics and new quantitative probe tests; therapeutics, with an emphasis on oncology and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. ; pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. and adult vaccines; and ophthalmic surgical products for the correction of vision. Chiron also has research programs underway in gene therapy, combinatorial chemistry, cancer, infectious and cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and critical care through its Chiron Technologies business unit. CONTACT: Chiron Corporation Larry Kurtz, 510/601-2476 Kimberly Sankaran, 510/601-2412 or Marketing Plus (for Biometric Imaging) Siga Weber, 415/421-8200 or Biometric Imaging Christina Lowell, 415/903-5870 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion